Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Merck
Express Scripts
McKinsey

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Patent: 9,809,588

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,809,588
Title:GLS1 inhibitors for treating disease
Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: ##STR00001## Methods of inhibition GLS1 activity in a human or animal subject are also provided.
Inventor(s): Di Francesco; Maria Emilia (Houston, TX), Jones; Philip (Houston, TX), Heffernan; Timothy (Sugar Land, TX), Hamilton; Matthew M. (Missouri City, TX), Kang; Zhijun (Sugar Land, TX), Soth; Michael J. (Sugar Land, TX), Burke; Jason P. (Houston, TX), Le; Kang (Sugar Land, TX), Carroll; Christopher Lawrence (Houston, TX), Palmer; Wylie S. (Houston, TX), Lewis; Richard (Houston, TX), McAfoos; Timothy (Houston, TX), Czako; Barbara (Houston, TX), Liu; Gang (Sugar Land, TX), Theroff; Jay (Manvel, TX), Herrera; Zachary (Houston, TX), Yau; Anne (Houston, TX)
Assignee: Board of Regents, The University of Texas System (Austin, TX)
Application Number:14/791,186
Patent Claims:see list of patent claims

Details for Patent 9,809,588

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Board of Regents, The University of Texas System (Austin, TX) 2034-07-03 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Board of Regents, The University of Texas System (Austin, TX) 2034-07-03 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Board of Regents, The University of Texas System (Austin, TX) 2034-07-03 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Board of Regents, The University of Texas System (Austin, TX) 2034-07-03 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Board of Regents, The University of Texas System (Austin, TX) 2034-07-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,809,588

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Johnson and Johnson
McKesson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.